A Study to Investigate the Effectiveness, Safety, and Tolerability of MAG200 Solution for Intra-articular Injection Compared With Placebo in Participants Aged 35 to 75 Years of Age With Symptomatic Osteoarthritis of the Knee.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: allogeneic human adipose-derived mesenchymal stem cells, Placebo.
- Who it may be relevant to
- Registry conditions: Knee Osteoarthristis. Basic parameters: 35 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase 3, Multicentre, Randomised, Double Blind, Placebo-controlled Study to Evaluate the Effectiveness, Safety, and Tolerability of MAG200 (an Allogeneic Adipose-derived Mesenchymal Stem Cell Preparation) Administered by Intra-articular Injection to Adult Participants With Symptomatic Osteoarthritis of the Knee.
Overview
The purpose of this study is to confirm whether MAG200 (20M or 100M) will improve pain and function of participants with osteoarthritis of the knee compared with placebo. In addition, the two strengths of MAG200 will be compared. In this study, participants will receive a single injection of placebo or allogeneic ADMSCs (MAG200) administered by IA injection. Participants will be randomised to receive placebo, or MAG200 at a dose of 20 million cells (20M), or MAG200 at a dose of 100 million cells (100M). It is anticipated that the study will run for approximately 48 months.
Interventions
- Biological allogeneic human adipose-derived mesenchymal stem cells
The Investigational Product MAG200 is a preparation of 5 mL allogeneic human adipose-derived mesenchymal stem cells (MSCs). - Other Placebo
Placebo is commercially available injectable normal saline (0.9% Sodium Chloride in Water for Injection)
Primary outcome measures
- To assess the effect of MAG200 on osteoarthritis pain and function [Time frame: 12 months]
Secondary outcome measures (3)
- To assess the effect of MAG200 on osteoarthritis pain [Time frame: 1, 3, 6, 9, and 12 months]
- To assess the response rate of MAG200 [Time frame: 1, 3, 6, 9, and 12 months]
- To assess the effect of MAG200 on radiological progression [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Males and females aged ≥ 35 years to ≤ 75 years inclusive.
- BMI ≥ 19.0 to ≤ 35.0 kg/m2.
- Documented clinical diagnosis of OA of the study knee.
- Documented radiological grading of Grade 2 or Grade 3 medial and/or lateral compartment OA of the study knee.
- Documented radiological grading of OARSI JSN 1-2 of the medial and/or lateral compartment of the study knee.
- Primary OA treatment of the study knee already attempted within the last 12 months, defined as:
- Prescribed analgesia/anti-inflammatory medication where appropriate, AND
- an attempted exercise program prescribed by a physical therapist (e.g., physiotherapist, osteopath) or medical practitioner for at least 8 weeks, AND
- weight management, where appropriate.
- Moderate to severe knee specific activity related pain score on the NRS for Pain over the past week.
- Moderate to severe knee specific functional limitation on KOOS-PS.
- Less than 5 degrees varus or valgus knee deformity of the study knee relative to neutral alignment.
Exclusion criteria
- Any of the following relating to the study knee:
- Radiological evidence of KL Grade 4 OA (involving medial, lateral and/or patellofemoral compartment) or OARSI JSN 3.
- History of recurrent mechanical instability and / or locking.
- Joint surgery or significant knee injury within 12 months prior to Day 1.
- Metal in-situ resulting in metal artefact which impacts/prevents MRI assessment.
- MRI confirmed:
i. Generalised full thickness chondral loss involving tibial and/or femoral weight bearing surfaces ii. Total meniscectomy iii. Complete posterior meniscal root tear iv. Subchondral insufficiency fracture v. Osteonecrosis vi. Malignant bone marrow infiltration vii. Solid tumors viii. Traumatic fracture/bone contusion ix. Knee pathology requiring orthopaedic assessment/intervention (e.g., significant loose body)
- Other causes of the knee symptoms unrelated to knee OA.
- Significant and debilitating OA in the non-study knee.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07106229 · MSC-OAK-003